A CLINICO COMPARATIVE STUDY OF PANCHASAMA CHOORNA WITH AND WITHOUT VALUKA SWEDA IN AMAVATA W.S.R. RHEUMATOID ARTHRITIS
DOI:
https://doi.org/10.70066/jahm.v3i6.277Keywords:
Amavata, Panchasama choorna, valuka sweda, Rheumatoid arthritis.Abstract
Background: Amavata which can be compared to Rheumatoid arthritis is a clinical condition where low
digestive power plays an important role. Panchasama choorna helps in the management of Amavata by
increasing digestive power, clearing the channels of circulation, reduces inflammation and pain when
administered with fomentation. Objectives: 1.To compare the efficacy of trial drug Panchasama choorna
individually as well as with valuka sweda (fomentation by sand bolus). 2. To establish a safe, economical and
effective medication for Amavata without side effect. Method: In this study 30 patients were selected
satisfying the inclusion criteria and randomly divided into two groups. In Group A– Panchasama choorna 4gms
TID was administered for 30 days with Luke warm water. In Group B – Panchasama choorna 4gms TID with
Luke warm water was administered for 30 days with valuka sweda for 15 days. Severity of the disease was
assessed based on selected subjective and objective parameters. Results: After trial, it was observed that
better and sustained relief with respect to all the signs and symptoms were observed in group B which is
treated with combined therapy. Overall assessment shows marked, moderate, mild improvement and
unchanged as 20%, 46.7%, 26.7% & 6.7% respectively among group B patients. Conclusion: The drug
Panchasama choorna was found to be highly significant in providing symptomatic relief when administered
along with valuka sweda
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Nagendra Prasad
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain the copyright of their work and grant the Journal of Ayurveda and Holistic Medicine (JAHM) the right of first publication. All published articles are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license, which permits non-commercial sharing, use, distribution, and adaptation with proper attribution and the same license terms.
JAHM ensures free, irrevocable, worldwide access to its content. Users may copy, distribute, display, and share published works for non-commercial purposes with appropriate credit to the author(s) and the journal. Limited printed copies for personal, non-commercial use are allowed under the same license.
If a submission is not accepted for publication, the author(s) will be notified.
By submitting, authors confirm that the work is original, that all listed authors have contributed and approved it, and that it does not infringe any third-party rights or duplicate work submitted elsewhere.
